Astrocytoma, IDH-Mutant, Grade 2
specificIDH-mutant astrocytoma characterized by the presence of necrosis and/or microvascular proliferation or homozygous deletion of CDKN2A and/or CDKN2B genes. The term glioblastoma no longer applies to central nervous system WHO grade 4 IDH-mutant astrocytomas. (WHO 2021)
37
Centers
46
Active Trials
—
Cancer Funding
Top Centers for Astrocytoma, IDH-Mutant, Grade 2(37)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | University of Virginia Cancer CenterCharlottesville, VA NCI Comprehensive High-Volume Research Center | 73.2 |
| 2 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive Active Research Program | 68.4 |
| 3 | Siteman Cancer CenterSt. Louis, MO NCI Comprehensive Active Research Program | 68.4 |
| 4 | Herbert Irving Comprehensive Cancer CenterNew York, NY NCI Comprehensive Active Research Program | 68.4 |
| 5 | UC San Diego Moores Cancer CenterLa Jolla, CA NCI Comprehensive Active Research Program | 68.4 |
| 6 | NCI Comprehensive Active Research Program | 68.4 |
| 7 | NCI Clinical Active Research Program | 68.4 |
| 8 | Boston University Cancer CenterBoston, MA Active Research Program | 68.4 |
| 9 | Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive Active Research Program | 46.5 |
| 10 | Fred Hutch Cancer CenterSeattle, WA NCI Comprehensive Active Research Program | 46.5 |
| 11 | NCI Comprehensive Active Research Program | 46.5 |
| 12 | University of Michigan Rogel Cancer CenterAnn Arbor, MI NCI Comprehensive Active Research Program | 46.5 |
| 13 | Stanford Cancer InstitutePalo Alto, CA NCI Comprehensive Active Research Program | 46.5 |
| 14 | Mayo Clinic Comprehensive Cancer CenterRochester, MN NCI Comprehensive Active Research Program | 46.5 |
| 15 | Yale Cancer Center Yale School of MedicineNew Haven, CT NCI Comprehensive Active Research Program | 46.5 |
| 16 | Vanderbilt-Ingram Cancer CenterNashville, TN NCI Comprehensive Active Research Program | 46.5 |
| 17 | NCI Comprehensive Active Research Program | 46.5 |
| 18 | Duke Cancer InstituteDurham, NC NCI Comprehensive Active Research Program | 46.5 |
| 19 | Winship Cancer InstituteAtlanta, GA NCI Comprehensive Active Research Program | 46.5 |
| 20 | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH NCI Comprehensive Active Research Program | 46.5 |
| 21 | NCI Comprehensive Active Research Program | 46.5 |
| 22 | City of Hope Comprehensive Cancer CenterDuarte, CA NCI Comprehensive Active Research Program | 46.5 |
| 23 | University of Colorado Cancer CenterAurora, CO NCI Comprehensive Active Research Program | 46.5 |
| 24 | Moffitt Cancer CenterTampa, FL NCI Comprehensive Active Research Program | 46.5 |
| 25 | UC Davis Comprehensive Cancer CenterSacramento, CA NCI Comprehensive Active Research Program | 46.5 |
| 26 | The University of Arizona Cancer CenterTucson, AZ NCI Comprehensive Active Research Program | 46.5 |
| 27 | NCI Comprehensive Active Research Program | 46.5 |
| 28 | Medical College of Wisconsin Cancer CenterMilwaukee, WI Active Research Program | 46.5 |
| 29 | VCU Massey Comprehensive Cancer CenterRichmond, VA NCI Comprehensive Active Research Program | 46.5 |
| 30 | Cleveland Clinic Cancer CenterCleveland, OH Active Research Program | 46.5 |
| 31 | Holden Comprehensive Cancer CenterIowa City, IA NCI Comprehensive Active Research Program | 46.5 |
| 32 | The University of Kansas Cancer CenterKansas City, KS NCI Comprehensive Active Research Program | 46.5 |
| 33 | Rutgers Cancer InstituteNew Brunswick, NJ NCI Comprehensive Active Research Program | 46.5 |
| 34 | University of Illinois Cancer CenterChicago, IL Active Research Program | 46.5 |
| 35 | Cancer Center at IllinoisUrbana, IL Active Research Program | 46.5 |
| 36 | Mayo Clinic Comprehensive Cancer Center, FloridaJacksonville, FL Active Research Program | 46.5 |
| 37 | Mayo Clinic Comprehensive Cancer Center, ArizonaScottsdale, AZ Active Research Program | 46.5 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →